Radioactive Iodine Most Effective Treatment for Hyperthyroidism
|
By MedImaging International staff writers Posted on 12 Feb 2020 |
New guidelines issued in the UK for the treatment of hyperthyroidism, including Graves' disease, place heavier emphasis on the use of radioactive iodine as the frontline treatment for patients unlikely to remain remission-free on medication.
The guideline summary, compiled by researchers from the Royal College of Physicians (London, UK), the University of Birmingham (UB; United Kingdom), and the Royal College of Obstetricians and Gynaecologists (London, UK), are part of broader guidelines on thyroid disease issued by the UK National Institute for Health and Care Excellence ((NICE; London, United Kingdom), which concludes that radioactive iodine results in cure in as many as 90% of hyperthyroidism cases.
The new NICE guidelines cite five randomized controlled trials of people with hyperthyroid disease, which collectively indicate that long-term outcomes were improved with radioactive iodine treatment compared with antithyroid drugs, despite the former having a higher risk of thyroid eye disease (also known as Graves' ophthalmopathy). In addition, eight nonrandomized studies show no evidence of a clinically important increase in cancer diagnoses or deaths between those treated with radioactive iodine and healthy controls. The guideline was published on January 29, 2020, in BMJ.
“The strongest arguments in favor of radioactive iodine as a first-line therapy were the likelihood of inducing remission of Graves' disease with radioactive iodine, the finding that radioiodine is a safe treatment, and the reduction in the need for patients to remain on antithyroid drugs, which may have significant side effects,” said senior author Kristien Boelaert, MD, PhD, of UB. “We are very pleased to have been able to work with NICE to provide clear new guidance which we hope will improve outcomes for patients with this condition.”
Most cases of hyperthyroidism are due to Graves’ disease, an autoimmune disease of the thyroid, an endocrine gland in the neck that produces two hormones secreted into the bloodstream, thyroxine (T4) and triiodothyronine (T3); T4 is converted to T3 in cells and tissues. The hormones regulate metabolism. Thyroid disorders include hypothyroidism, hyperthyroidism, nodules, cancer, Graves’ disease, and post-partum thyroiditis. The prevalence of hyperthyroidism is about 1.2% (0.5% overt and 0.7% subclinical).
Related Links:
Royal College of Physicians
University of Birmingham
Royal College of Obstetricians and Gynaecologists
UK National Institute for Health and Care Excellence
The guideline summary, compiled by researchers from the Royal College of Physicians (London, UK), the University of Birmingham (UB; United Kingdom), and the Royal College of Obstetricians and Gynaecologists (London, UK), are part of broader guidelines on thyroid disease issued by the UK National Institute for Health and Care Excellence ((NICE; London, United Kingdom), which concludes that radioactive iodine results in cure in as many as 90% of hyperthyroidism cases.
The new NICE guidelines cite five randomized controlled trials of people with hyperthyroid disease, which collectively indicate that long-term outcomes were improved with radioactive iodine treatment compared with antithyroid drugs, despite the former having a higher risk of thyroid eye disease (also known as Graves' ophthalmopathy). In addition, eight nonrandomized studies show no evidence of a clinically important increase in cancer diagnoses or deaths between those treated with radioactive iodine and healthy controls. The guideline was published on January 29, 2020, in BMJ.
“The strongest arguments in favor of radioactive iodine as a first-line therapy were the likelihood of inducing remission of Graves' disease with radioactive iodine, the finding that radioiodine is a safe treatment, and the reduction in the need for patients to remain on antithyroid drugs, which may have significant side effects,” said senior author Kristien Boelaert, MD, PhD, of UB. “We are very pleased to have been able to work with NICE to provide clear new guidance which we hope will improve outcomes for patients with this condition.”
Most cases of hyperthyroidism are due to Graves’ disease, an autoimmune disease of the thyroid, an endocrine gland in the neck that produces two hormones secreted into the bloodstream, thyroxine (T4) and triiodothyronine (T3); T4 is converted to T3 in cells and tissues. The hormones regulate metabolism. Thyroid disorders include hypothyroidism, hyperthyroidism, nodules, cancer, Graves’ disease, and post-partum thyroiditis. The prevalence of hyperthyroidism is about 1.2% (0.5% overt and 0.7% subclinical).
Related Links:
Royal College of Physicians
University of Birmingham
Royal College of Obstetricians and Gynaecologists
UK National Institute for Health and Care Excellence
Latest Nuclear Medicine News
- Portable PET System Enables Real-Time Bedside Guidance for Biopsies and Ablations
- AI Model Predicts Radiation Dose Before Prostate Cancer Therapy
- Vault-Free Radiosurgery Platform Expands Access to Cranial Tumor Care
- MR-Guided Cardiac Mapping System Enables Radiation-Free Procedures
- New Imaging Tool Sheds Light on Tumor Fat Metabolism
- PET Tracer Enables Noninvasive Measurement of Beta Cell Mass
- Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies
- Cancer “Flashlight” Shows Who Can Benefit from Targeted Treatments
- PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack
- Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers
- New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer
- PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers
- New Camera Sees Inside Human Body for Enhanced Scanning and Diagnosis
- Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections
- New Imaging Approach Could Reduce Need for Biopsies to Monitor Prostate Cancer
- Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
Channels
Radiography
view channel
AI Tool Flags Osteoporosis Risk from Routine Chest X-Rays
Osteoporosis is a progressive loss of bone density that is often silent until a fracture occurs. Current screening frameworks concentrate on older women and select high-risk groups. Many men, younger adults,... Read more
Simple Chest X-Ray Measure Predicts Survival After Lung Cancer Surgery
Obstructive ventilatory disorder, marked by airflow limitation that reduces breathing efficiency, increases postoperative risk in patients with lung cancer. Although surgery offers the best chance of cure,... Read moreMRI
view channel
AI Approach Could Shorten Advanced Brain MRI Scans by Up to 90%
Long acquisition times for advanced brain magnetic resonance imaging (MRI) can limit access, extend waiting lists, and disrupt clinical workflows. Reducing data requirements without sacrificing image fidelity... Read more
Cardiac MRI Measure Improves Risk Prediction in Tricuspid Regurgitation
Tricuspid regurgitation, in which blood flows back from the right ventricle into the right atrium, can lead to progressive right-sided heart failure. Clinicians need reliable ways to gauge severity and... Read moreUltrasound
view channelAI Robotic Ultrasound System Automates Echocardiography and Improves Consistency
Echocardiography, an ultrasound examination of the heart, is central to diagnosing and managing cardiovascular disease. Many services struggle with limited availability of skilled sonographers, variable... Read more
Whole Cross-Section Ultrasound System Enables Operator-Independent Imaging
Conventional ultrasound is central to bedside imaging but is limited by a narrow field of view and operator variability. Comprehensive cross-sectional assessment typically requires computed tomography... Read moreGeneral/Advanced Imaging
view channel
Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
Obesity surgery improves weight and comorbidity profiles, yet clinicians lack tools to monitor organ-level metabolic recovery after the procedure. A clear view of systemic changes could refine follow-up... Read more
PET Tracer Localizes Overactive Adrenal Glands in Primary Aldosteronism
Primary aldosteronism (Conn’s syndrome) is the leading cause of curable secondary hypertension and results from excess aldosterone produced by the adrenal cortex. Determining whether hormone overproduction... Read moreImaging IT
view channel
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read moreIndustry News
view channel
GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare is highlighting Intelligent Radiation Therapy (iRT), MIM Software innovations, and BK Medical surgical... Read more







